Discontinued — last reported Q4 '25
Non-Current Assets
PP&E (Net)
Vertex Pharmaceuticals PP&E (Net) increased by 6.7% to $1.52B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 23.8%, from $1.23B to $1.52B. Over 5 years (FY 2020 to FY 2025), PP&E (Net) shows an upward trend with a 9.7% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2014
Last reportedQ4 2025Feb 13, 2026
How to read this metric
An increase indicates ongoing investment in physical capacity, whereas a decline may suggest aging assets or a strategy of asset-light operations.
Detailed definition
This metric represents the book value of tangible assets after subtracting accumulated depreciation from the total histo...
Peer comparison
Standard line item for all manufacturing and industrial companies; directly comparable across peers.
Metric ID:
property_plant_equipment_netHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.02B | $1.04B | $1.09B | $1.11B | $1.10B | $1.12B | $1.11B | $1.11B | $1.12B | $1.12B | $1.16B | $1.17B | $1.20B | $1.12B | $1.23B | $1.30B | $1.34B | $1.43B | $1.52B |
| QoQ Change | — | +2.1% | +5.0% | +1.2% | -0.7% | +1.7% | -0.9% | +0.3% | +1.0% | +0.1% | +3.1% | +1.2% | +2.4% | -6.9% | +9.8% | +5.5% | +3.0% | +6.7% | +6.7% |
| YoY Change | — | — | — | — | +7.7% | +7.3% | +1.3% | +0.4% | +2.0% | +0.5% | +4.6% | +5.5% | +7.0% | -0.6% | +5.9% | +10.5% | +11.2% | +27.5% | +23.8% |
Range$1.02B – $1.52B
CAGR+9.2%
Avg YoY Growth+7.6%
Median YoY Growth+5.9%
Current Streak5 quarters growth
Geographic Breakdown — United States
| Segment | Q4 '24 |
|---|---|
| United States | $2.39B |
| United Kingdom | $176.60M |
| Total | $1.23B |
Geographic Breakdown — Total revenues outside of the United States
| Segment | Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 |
|---|---|---|---|---|---|
| Total revenues outside of the United States | $76.30M | $90.30M | $93.20M | $192.20M | $194.60M |
| Other | — | — | — | $15.60M | — |
| Total | $1.09B | $1.11B | $1.16B | $1.23B | $1.52B |
PP&E (Net) at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's pp&e (net)?
- Vertex Pharmaceuticals (VRTX) reported pp&e (net) of $1.52B in Q4 2025.
- How has Vertex Pharmaceuticals's pp&e (net) changed year-over-year?
- Vertex Pharmaceuticals's pp&e (net) increased by 23.8% year-over-year, from $1.23B to $1.52B.
- What is the long-term trend for Vertex Pharmaceuticals's pp&e (net)?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's pp&e (net) has grown at a 9.7% compound annual growth rate (CAGR), from $958.50M to $1.52B.
- What does pp&e (net) mean?
- The current book value of physical assets after accounting for wear and tear.